ThinkstockRepros Therapeutics Inc. (NASDAQ: RPRX) is surging on clinical update news this Thursday. The company’s Androxal Phase 3 program has been given a receipt of written guidance from the Food & Drug Administration. This…
ThinkstockAmbit Biosciences Corp. has filed its paperwork with the Securities and Exchange Commission to come public via an initial public offering. No financial terms have been given other than that its initial filing is…
ThinkstockWhen Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) announced that the U.S. Food & Drug Administration was going to allow the company to submit its market approval application for Northera using the existing study data,…
ThinkstockWhen companies start buying back their common stock on the open market, it can have multiple outcomes. It can offset employee stock option dilution, and it can lower the public share float. It can…
ThinkstockHumana Inc. (NYSE: HUM) is leading the large health insurance providers lower as the week gets off to a start. The news hit going into the weekend that the Centers for Medicare and Medicaid…
ThinkstockExpress Scripts Holding Co. (NASDAQ: ESRX) reported fourth-quarter and full-year 2012 results yesterday. For the quarter, the pharmacy benefits management company posted adjusted diluted earnings per share (EPS) of $1.05 on revenues of $27.41…
We wrote at great length last month about the Key Call and Conviction Buy lists from the major Wall St. firms, bulge bracket and otherwise. The reason these lists are important for the individual…
ThinkstockInvesting in biotech or biopharmaceutical stocks can prove to be a very daunting task. Many of the stocks have limited pipelines or their very survival depends on a single binary event that may require…
ThinkstockOncolytics Biotech Inc. (NASDAQ: ONCY) just reasserted its position on the map again. The company has announced test results showing tumor shrinkage data from its U.S. Phase II clinical trial in patients with squamous…
ThinkstockHave some widely owned health care names hit a wall when it comes to growth and earnings? In a research report issued today, Credit Suisse Group Inc. (NYSE: CS) issues some not very enthusiastic…
ThinkstockBiogen Idec Inc. (NASDAQ: BIIB) may be a half decade or so late on this move, but as the saying goes “better late than never.” The biotech and drug company is the leader in multiple sclerosis…
ThinkstockOpexa Therapeutics Inc. (NASDAQ: OPXA) is not just soaring this Tuesday. It is rising exponentially after securing an option and license agreement with Merck Serono on its multiple sclerosis treatment. The reason this is…
ThinkstockHumana Inc. (NYSE: HUM) reported fourth-quarter and full-year 2012 results before markets opened this morning. For the quarter, the health care company posted diluted earnings per share (EPS) of $1.19 on revenues of $9.56…
ThinkstockZoetis Inc. (NYSE: ZTS), a spin-off of the animal health business of Pfizer Inc. (NYSE: PFE), held its initial public offering this morning. The company offered 86.1 million shares at $26 a share, $1.00…
ThinkstockAccording to the Centers for Disease Control (CDC), more than one-third (35.7%) of all adults in the United States are obese or very overweight. Obesity-related medical conditions include heart attack, stroke, type-2 diabetes and…